1. The COVID-19 pandemic has highlighted the need for cost-effective diagnostics for SARS-CoV-2 RNA as well as for the detection of antibodies generated by the host in response to infection.
2. Molecular diagnostics that detect the presence of viral RNA are key to detecting the virus during the first 5 days of infection, while serological assays can detect antibodies developed after an infection and provide insights into patient progression.
3. A lab-on-a-chip is proposed for concurrent electrochemical detection of SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies in saliva and plasma, which could improve accuracy of diagnosis and provide qualitative data on disease severity and state of progression.
The article “A lab-on-a chip for the concurrent electrochemical detection of SARS-CoV-2 RNA and anti-SARS CoV 2 antibodies in saliva and plasma” is a reliable source that provides a comprehensive overview of current methods used to diagnose SARS CoV 2 infections, as well as potential solutions such as a lab on a chip device that could be used to concurrently detect both viral RNA and antibodies in clinical samples. The article is written in an objective manner, presenting both sides equally without any bias or promotional content. It also provides evidence to support its claims, such as citing studies that have shown correlations between antibody titres and disease severity or vaccine efficacy. Furthermore, it acknowledges possible risks associated with using this type of device, such as false positives or negatives due to cross reactivity with other viruses or antigens. In conclusion, this article is trustworthy and reliable source that provides an unbiased overview of current methods used to diagnose SARS CoV 2 infections, as well as potential solutions such as a lab on a chip device that could be used to concurrently detect both viral RNA and antibodies in clinical samples.